Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. [electronic resource]
Producer: 20180530Description: 650-657 p. digitalISSN:- 2152-2669
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bortezomib -- administration & dosage
- Busulfan -- administration & dosage
- Consolidation Chemotherapy
- Female
- Graft Survival
- Hematopoietic Stem Cell Transplantation
- Humans
- Kaplan-Meier Estimate
- Maintenance Chemotherapy
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Multiple Myeloma -- diagnosis
- Retreatment
- Survival Analysis
- Transplantation Conditioning -- methods
- Transplantation, Autologous
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.